First Time Loading...
I

Immune Pharmaceuticals Inc
OTC:IMNPQ

Watchlist Manager
Immune Pharmaceuticals Inc
OTC:IMNPQ
Watchlist
Price: 0.001 USD Market Closed
Updated: May 17, 2024

Immune Pharmaceuticals Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Immune Pharmaceuticals Inc
Interest Income Expense Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
I
Immune Pharmaceuticals Inc
OTC:IMNPQ
Interest Income Expense
-$3.5m
CAGR 3-Years
4%
CAGR 5-Years
-181%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Interest Income Expense
-$1.8B
CAGR 3-Years
8%
CAGR 5-Years
-7%
CAGR 10-Years
-19%
Gilead Sciences Inc
NASDAQ:GILD
Interest Income Expense
-$757m
CAGR 3-Years
35%
CAGR 5-Years
0%
CAGR 10-Years
-10%
Amgen Inc
NASDAQ:AMGN
Interest Income Expense
-$2.9B
CAGR 3-Years
-44%
CAGR 5-Years
-30%
CAGR 10-Years
-16%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Interest Income Expense
$563.1m
CAGR 3-Years
78%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Interest Income Expense
$221.8m
CAGR 3-Years
-13%
CAGR 5-Years
75%
CAGR 10-Years
N/A

See Also

What is Immune Pharmaceuticals Inc's Interest Income Expense?
Interest Income Expense
-3.5m USD

Based on the financial report for Dec 31, 2017, Immune Pharmaceuticals Inc's Interest Income Expense amounts to -3.5m USD.

What is Immune Pharmaceuticals Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-181%

Over the last year, the Interest Income Expense growth was 66%. The average annual Interest Income Expense growth rates for Immune Pharmaceuticals Inc have been 4% over the past three years , -181% over the past five years .